Cargando…
Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization
INTRODUCTION: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. Th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221541/ https://www.ncbi.nlm.nih.gov/pubmed/28115842 http://dx.doi.org/10.2147/COPD.S118424 |
_version_ | 1782492839585775616 |
---|---|
author | Dilektasli, Asli Gorek Demirdogen Cetinoglu, Ezgi Uzaslan, Esra Budak, Ferah Coskun, Funda Ursavas, Ahmet Ercan, Ilker Ege, Ercument |
author_facet | Dilektasli, Asli Gorek Demirdogen Cetinoglu, Ezgi Uzaslan, Esra Budak, Ferah Coskun, Funda Ursavas, Ahmet Ercan, Ilker Ege, Ercument |
author_sort | Dilektasli, Asli Gorek |
collection | PubMed |
description | INTRODUCTION: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. MATERIALS AND METHODS: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. RESULTS: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P<0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P<0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. CONCLUSION: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores. |
format | Online Article Text |
id | pubmed-5221541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52215412017-01-23 Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization Dilektasli, Asli Gorek Demirdogen Cetinoglu, Ezgi Uzaslan, Esra Budak, Ferah Coskun, Funda Ursavas, Ahmet Ercan, Ilker Ege, Ercument Int J Chron Obstruct Pulmon Dis Original Research INTRODUCTION: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. MATERIALS AND METHODS: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. RESULTS: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P<0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P<0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. CONCLUSION: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores. Dove Medical Press 2017-01-05 /pmc/articles/PMC5221541/ /pubmed/28115842 http://dx.doi.org/10.2147/COPD.S118424 Text en © 2017 Dilektasli et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Dilektasli, Asli Gorek Demirdogen Cetinoglu, Ezgi Uzaslan, Esra Budak, Ferah Coskun, Funda Ursavas, Ahmet Ercan, Ilker Ege, Ercument Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title_full | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title_fullStr | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title_full_unstemmed | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title_short | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
title_sort | serum ccl-18 level is a risk factor for copd exacerbations requiring hospitalization |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221541/ https://www.ncbi.nlm.nih.gov/pubmed/28115842 http://dx.doi.org/10.2147/COPD.S118424 |
work_keys_str_mv | AT dilektasliasligorek serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT demirdogencetinogluezgi serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT uzaslanesra serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT budakferah serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT coskunfunda serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT ursavasahmet serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT ercanilker serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization AT egeercument serumccl18levelisariskfactorforcopdexacerbationsrequiringhospitalization |